Latest Guidelines for Preventing MI and Death in Patients With Cardiovascular Disease

News
Article

Many of the approximately 12.4 million Americans whohave cardiovascular disease are not being treated with themost up-to-date risk-reduction therapies.1 Strong evidencefrom recent studies, such as the National Heart, Lung, andBlood Institute’s Adult Treatment Panel III report2 and theHeart Outcomes Prevention Evaluation (HOPE) trial,3demonstrate the need for more aggressive use of appropriatemedical and lifestyle therapies for these patients.

Many of the approximately 12.4 million Americans whohave cardiovascular disease are not being treated with themost up-to-date risk-reduction therapies.1 Strong evidencefrom recent studies, such as the National Heart, Lung, andBlood Institute's Adult Treatment Panel III report2 and theHeart Outcomes Prevention Evaluation (HOPE) trial,3demonstrate the need for more aggressive use of appropriatemedical and lifestyle therapies for these patients.

The American Heart Association and the AmericanCollege of Cardiology recently updated their 1995 guidelinesto reflect the latest data (Table).

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2025 MJH Life Sciences

All rights reserved.